Detalhe da pesquisa
1.
Upadacitinib Achieves Clinical and Endoscopic Outcomes in Crohn's Disease Regardless of Prior Biologic Exposure.
Clin Gastroenterol Hepatol
; 2024 Mar 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38492904
2.
Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial.
Lancet
; 399(10340): 2031-2046, 2022 05 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-35644155
3.
Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials.
Lancet
; 399(10340): 2015-2030, 2022 05 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-35644154
4.
Maintenance Risankizumab Sustains Induction Response in Patients with Crohn's Disease in a Randomized Phase 3 Trial.
J Crohns Colitis
; 18(3): 416-423, 2024 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37797293
5.
Effect of risankizumab on health-related quality of life in patients with Crohn's disease: results from phase 3 MOTIVATE, ADVANCE and FORTIFY clinical trials.
Aliment Pharmacol Ther
; 57(5): 496-508, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36266762
6.
Association of Biomarker Cutoffs and Endoscopic Outcomes in Crohn's Disease: A Post Hoc Analysis From the CALM Study.
Inflamm Bowel Dis
; 26(10): 1562-1571, 2020 09 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-32105310
7.
Efficacy and Safety of Adalimumab by Disease Duration: Analysis of Pooled Data From Crohn's Disease Studies.
J Crohns Colitis
; 13(6): 725-734, 2019 May 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-30753371
8.
Adalimumab Effectiveness Up to Six Years in Adalimumab-naïve Patients with Crohn's Disease: Results of the PYRAMID Registry.
Inflamm Bowel Dis
; 25(9): 1522-1531, 2019 08 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-30753510
9.
Clinical Benefit of Long-Term Adalimumab Treatment in Patients With Crohn's Disease Following Loss of Response or Intolerance to Infliximab: 96-Week Efficacy Data From GAIN/ADHERE Trials.
J Crohns Colitis
; 12(8): 930-938, 2018 Jul 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-29697818
10.
Adalimumab Reduces Extraintestinal Manifestations in Patients with Crohn's Disease: A Pooled Analysis of 11 Clinical Studies.
Adv Ther
; 35(4): 563-576, 2018 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-29516410